 Proto-Oncogene Proteins c-met
"Proto-Oncogene Proteins c-met" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface protein-tyrosine kinase receptors for HEPATOCYTE GROWTH FACTOR. They consist of an extracellular alpha chain which is disulfide-linked to the transmembrane beta chain. The cytoplasmic portion contains the catalytic domain and sites critical for the regulation of kinase activity. Mutations of the gene for PROTO-ONCOGENE PROTEINS C-MET are associated with papillary renal carcinoma and other neoplasia.
| Descriptor ID |
D019859
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.075 D12.776.543.750.060.186 D12.776.543.750.750.400.100 D12.776.624.664.700.186
|
| Concept/Terms |
Proto-Oncogene Proteins c-met- Proto-Oncogene Proteins c-met
- Proto Oncogene Proteins c met
- Hepatocyte Growth Factor Receptor
- HGF Receptor
- Scatter Factor Receptor
- Receptor, Hepatocyte Growth Factor
- Receptor, HGF
- Receptor, Scatter Factor
- c-met Proteins
- c met Proteins
- met Proto-Oncogene Proteins
- Proto-Oncogene Proteins, met
- met Proto Oncogene Proteins
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-met".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-met".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-met" by people in this website by year, and whether "Proto-Oncogene Proteins c-met" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 | | 2002 | 2 | 0 | 2 | | 2003 | 3 | 2 | 5 | | 2004 | 2 | 0 | 2 | | 2005 | 3 | 0 | 3 | | 2006 | 1 | 0 | 1 | | 2007 | 11 | 2 | 13 | | 2008 | 3 | 3 | 6 | | 2009 | 7 | 3 | 10 | | 2010 | 7 | 2 | 9 | | 2011 | 8 | 2 | 10 | | 2012 | 2 | 0 | 2 | | 2013 | 9 | 0 | 9 | | 2014 | 7 | 0 | 7 | | 2015 | 2 | 2 | 4 | | 2016 | 2 | 2 | 4 | | 2017 | 3 | 0 | 3 | | 2018 | 2 | 1 | 3 | | 2019 | 2 | 0 | 2 | | 2020 | 4 | 2 | 6 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-met" by people in Profiles.
-
Camidge DR, Morgensztern D, Heist RS, Barve M, Vokes E, Goldman JW, Hong DS, Bauer TM, Strickler JH, Angevin E, Motwani M, Parikh A, Sun Z, Bach BA, Wu J, Komarnitsky PB, Kelly K. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. Clin Cancer Res. 2021 11 01; 27(21):5781-5792.
-
Roth KG, Mambetsariev I, Salgia R. Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report. Cold Spring Harb Mol Case Stud. 2020 12; 6(6).
-
Apolo AB, Nadal R, Girardi DM, Niglio SA, Ley L, Cordes LM, Steinberg SM, Sierra Ortiz O, Cadena J, Diaz C, Mallek M, Davarpanah NN, Costello R, Trepel JB, Lee MJ, Merino MJ, Bagheri MH, Monk P, Figg WD, Gulley JL, Agarwal PK, Valera V, Chalfin HJ, Jones J, Streicher H, Wright JJ, Ning YM, Parnes HL, Dahut WL, Bottaro DP, Lara PN, Saraiya B, Pal SK, Stein MN, Mortazavi A. Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. J Clin Oncol. 2020 11 01; 38(31):3672-3684.
-
Malik R, Mambetsariev I, Fricke J, Chawla N, Nam A, Pharaon R, Salgia R. MET receptor in oncology: From biomarker to therapeutic target. Adv Cancer Res. 2020; 147:259-301.
-
Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 09 03; 383(10):931-943.
-
Salgia R, Sattler M, Scheele J, Stroh C, Felip E. The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treat Rev. 2020 Jul; 87:102022.
-
Strickler JH, LoRusso P, Salgia R, Kang YK, Yen CJ, Lin CC, Ansell P, Motwani M, Wong S, Yue H, Wang L, Reilly E, Afar D, Naumovski L, Ramanathan RK. Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2020 05; 19(5):1210-1217.
-
Falchook GS, Kurzrock R, Amin HM, Xiong W, Fu S, Piha-Paul SA, Janku F, Eskandari G, Catenacci DV, Klevesath M, Bruns R, Stammberger U, Johne A, Bladt F, Friese-Hamim M, Girard P, El Bawab S, Hong DS. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 03 15; 26(6):1237-1246.
-
Clark JW, Camidge DR, Kwak EL, Maki RG, Shapiro GI, Chen I, Tan W, Randolph S, Christensen JG, Ozeck M, Tang Y, Wilner KD, Salgia R. Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future Oncol. 2020 Jan; 16(1):4289-4301.
-
Sivakumar M, Jayakumar M, Seedevi P, Sivasankar P, Ravikumar M, Surendar S, Murugan T, Siddiqui SS, Loganathan S. Meta-analysis of functional expression and mutational analysis of c-Met in various cancers. Curr Probl Cancer. 2020 08; 44(4):100515.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|